Genmab — April 2016
-
-
As for possible M&A opportunities with biotech valuations coming down, Caruso said J&J is "obviously looking very closely at the field."
"[But] I'm not sure the owners of those companies agree the current valuations are at the right place. So we'll continue to work through various acquisition proposals," he added. "We want to do the right deal, at the right time, with the right partner, at the right valuation."
-
Caruso udelukkede i det hele taget ikke ret meget ang. anvendelse af JJs balance - hans mantra lød blot på maximum value for shareholders
-
men et par af analytikerne forholdt ham med deres overvældende overraskelse over JJs inaktivitet på området
-
Mcjean: Selvom de skulle betale en præmie på 100% så ved vi jo allesammen godt hvad potentialet er i GEN's pipeline. Synes også det lugter lidt af forhandlingsretorik, men lad os nu se. Jeg synes uanset hvad at det er kanon at få konkretiseret J&J's tanker på området
-
nu skal der jo lige være en 90% tilslutning fra aktionæernes side. Jeg forstår ikke helt, at alle drømmer om et salg. På den lange bane, ser det da glimrende ud, selv uden et salg
-
jeg er ikke tilhønger af et salg, hvor kan vi placerer pengene bedre
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
